Abstract
1104P Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have